Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
| Autor: | Xi-zhi Wen, Qiu-zhong Pan, Bu-shu Xu, Wei Xiao, De-sheng Weng, Jing-jing Zhao, Hai-rong Xu, Zhen Huang, Xiao-hui Niu, Xing Zhang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Adult Male Cancer Research Osteosarcoma Adolescent Dose-Response Relationship Drug Maximum Tolerated Dose Bone Neoplasms Toxicology Polyethylene Glycols Young Adult Treatment Outcome Oncology Doxorubicin Antineoplastic Combined Chemotherapy Protocols Humans Pharmacology (medical) Female Cisplatin |
| Zdroj: | Cancer chemotherapy and pharmacology. 89(2) |
| ISSN: | 1432-0843 |
| Popis: | The repeated use of doxorubicin is limited due to dose-limiting cardiac toxicity. Pegylated liposomal doxorubicin (PEG-LD, Duomeisu) has a reduced cardiac toxicity. This phase I study aimed to investigate the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the PEG-LD and cisplatin combination in patients with metastatic and recurrent osteosarcoma.Patients were given PEG-LD at a dose of 40, 50, or 60 mg/mA total of 15 patients were enrolled in this trial, and nine of the patients had received prior doxorubicin. The MTD of PEG-LD was reached at 50 mg/mWe provide the data showing that PEG-LD 50 mg/mChiCTR1900021550. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink